(0.05%) 5 251.33 points
(0.02%) 39 766 points
(-0.12%) 16 380 points
(1.99%) $82.97
(1.51%) $1.744
(1.22%) $2 239.70
(0.75%) $24.94
(1.28%) $921.35
(0.30%) $0.926
(0.76%) $10.85
(0.10%) $0.792
(0.14%) $92.57
Live Chart Being Loaded With Signals
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment...
Stats | |
---|---|
Today's Volume | 101 307 |
Average Volume | 345 228 |
Market Cap | 1.95B |
EPS | SEK0 ( 2024-02-21 ) |
Next earnings date | ( SEK-0.310 ) 2024-05-02 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -4.77 |
ATR14 | SEK0.0180 (0.27%) |
Volume Correlation
Egetis Therapeutics AB Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Egetis Therapeutics AB Correlation - Currency/Commodity
Egetis Therapeutics AB Financials
Annual | 2023 |
Revenue: | SEK57.60M |
Gross Profit: | SEK-126.80M (-220.14 %) |
EPS: | SEK-1.270 |
Q4 | 2023 |
Revenue: | SEK32.60M |
Gross Profit: | SEK-29.70M (-91.10 %) |
EPS: | SEK-0.300 |
Q3 | 2023 |
Revenue: | SEK12.20M |
Gross Profit: | SEK-41.70M (-341.80 %) |
EPS: | SEK-0.350 |
Q2 | 2023 |
Revenue: | SEK5.90M |
Gross Profit: | SEK-36.90M (-625.42 %) |
EPS: | SEK-0.320 |
Financial Reports:
No articles found.
Egetis Therapeutics AB
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators